| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥7.13B | -17.0% |
| Gross profit | ¥1.46B | — |
| Operating income | ¥0.71B | — |
| Net income | ¥0.54B | +1106.5% |
| Gross margin | 20.4% | Net margin 7.6% |
| Revenue Q/Q | -20.7% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥5.67B | 79.6% |
| R&D | ¥0.14B | 2.0% |
| SG&A | ¥0.50B | 7.0% |
| Tax & other | ¥0.17B | 2.3% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
百利天恒 ・ 芯原股份 ・ 中芯国际 ・ 特锐德 ・ 神州泰岳 ・ 乐普医疗 ・ 南风股份 ・ 探路者 ・ 莱美药业 ・ 汉威科技 ・ 天海防务 ・ 安科生物
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies